drugset / Trial / NCT00818623
Investigation of a New Trial Drug (FE200486) in Prostate Cancer Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this trial was to find an optimal dose for a new trial drug - degarelix (FE200486) - in the treatment of prostate cancer. Furthermore the safety of the drug was studied. Patients participating were treated with FE200486 on one occasion. Thereafter they came in for visits following a specific schedule until blood samples showed that there was no further effect.
Timeline
- Start
- 2002-11
- Primary completion
- 2004-10
- Completion
- 2004-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Degarelix | Other / unclassified | 120 mg | Subcutaneous |
| Subject | Degarelix | Other / unclassified | 160 mg | Subcutaneous |
| Subject | Degarelix | Other / unclassified | 200 mg | Subcutaneous |
| Subject | Degarelix | Other / unclassified | 240 mg | Subcutaneous |
| Subject | Degarelix | Other / unclassified | 320 mg | Subcutaneous |